Navigation Links
Cardium Reports On NYSE MKT Noncompliance Notice And Compliance Plan
Date:12/6/2012

sier to use or less expensive, that results or trends observed in one clinical study will be reproduced in subsequent studies, that third parties on whom we depend will behave as anticipated, or that necessary regulatory approvals will be obtained.  Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development, testing and marketing of biologics, medical devices and other products, and the conduct of human clinical trials, including the timing, costs and outcomes of such trials, whether our efforts to launch new products and expand our markets will be successful or completed within the time frames contemplated, our dependence upon proprietary technology, our ability to obtain necessary funding, regulatory approvals and qualifications, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other risks described from time to time in filings we make with the Securities and Exchange Commission.  We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.

Copyright 2012 Cardium Therapeutics, Inc.  All rights reserved.
For Terms of Use Privacy Policy, please visitwww.cardiumthx.com.

Cardium Therapeutics®, Generx®, Cardionovo™, Tissue Repair™, Gene Activated Matrix™, GAM™, Excellagen®, Excellarate™, Osteorate™, MedPodium®, Appexium®, Linée®<
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cardium to Present at Upcoming Investor Conferences
2. Cardium Presents First Quarter 2012 Financial Results and Recent Developments
3. Published Findings In Human Gene Therapy Methods Journal Demonstrate Cardiums New Catheter-Based Method Significantly Boosts Gene Delivery To The Heart
4. Cardium Announces Patent Award For Rights To Cardiovascular Gene Therapy For The Treatment Of Heart Disease
5. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
6. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
7. Interleukin Genetics Reports Third Quarter 2011 Financial Results
8. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
9. Nile Therapeutics Reports 2011 Third Quarter Financial Results
10. Pharmasset Reports Fiscal Year End 2011 Financial Results
11. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 30, 2015  Discovery Laboratories, Inc. (Nasdaq: ... the second $1.0M tranche under a previously awarded ... valued at up to $3.0 million to support ... as a potential medical countermeasure to mitigate acute ... awarded an initial $1.0 million under this grant ...
(Date:7/29/2015)... -- Sanofi, a global and diversified ... of 2015. CEO Olivier Brandicourt comments ... different businesses. Watch video interview and ... Topics covered in the interview include:  ... drivers - Diabetes - ...
(Date:7/29/2015)... US-Australian drug discovery company, Novogen Limited (ASX: ... committed to progressing its ground-breaking technology platforms to Phase ... ensure the Company delivers the best value for shareholders. ... , said the Company currently had an extensive program ... programs and academic partnerships and initiatives, and he was ...
(Date:7/29/2015)...  HealthSouth Corporation (NYSE: HLS ), one ... services, offering both facility-based and home-based post-acute services, ... second quarter ended June 30, 2015. ... growth in both segments and an 11.0% increase ... and Chief Executive Officer of HealthSouth. "While reported ...
Breaking Biology Technology:Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10HealthSouth Reports Results for Second Quarter 2015 2HealthSouth Reports Results for Second Quarter 2015 3HealthSouth Reports Results for Second Quarter 2015 4HealthSouth Reports Results for Second Quarter 2015 5HealthSouth Reports Results for Second Quarter 2015 6HealthSouth Reports Results for Second Quarter 2015 7HealthSouth Reports Results for Second Quarter 2015 8HealthSouth Reports Results for Second Quarter 2015 9HealthSouth Reports Results for Second Quarter 2015 10HealthSouth Reports Results for Second Quarter 2015 11HealthSouth Reports Results for Second Quarter 2015 12HealthSouth Reports Results for Second Quarter 2015 13HealthSouth Reports Results for Second Quarter 2015 14HealthSouth Reports Results for Second Quarter 2015 15HealthSouth Reports Results for Second Quarter 2015 16HealthSouth Reports Results for Second Quarter 2015 17HealthSouth Reports Results for Second Quarter 2015 18HealthSouth Reports Results for Second Quarter 2015 19HealthSouth Reports Results for Second Quarter 2015 20HealthSouth Reports Results for Second Quarter 2015 21HealthSouth Reports Results for Second Quarter 2015 22HealthSouth Reports Results for Second Quarter 2015 23HealthSouth Reports Results for Second Quarter 2015 24HealthSouth Reports Results for Second Quarter 2015 25
... , , , ... leading systems biology tools company, announced today that they ... International Society for Interferon and Cytokine Research (www.isicr.org). These ... and chemical pathway interactions. Each map describes multi-step signaling ...
... SYDNEY, July 21 /PRNewswire-Asia/ -- Pharmaxis Ltd (ASX: ... the afternoon of Wednesday,22nd July 2009. Dr Alan Robertson ... quarter and answer investor questions. , ... (Sydney),(Wednesday 22nd July at 6.00pm U.S. East Coast, 3.00pm U.S. ...
... Guo and his team of researchers for the project discovered a ... is pitch black, not by paint, but by using incredibly intense ... that shines upon it. "With the creation of the ... us, which may open up a whole new horizon for various ...
Cached Biology Technology:GeneGo Donates Proprietary Cytokine Pathway Maps to ISICR 2Laser technology creates new forms of metal and enhances aircraft performance 2
(Date:7/9/2015)... , July 9, 2015  Synaptics ... developer of human interface solutions, today announced ... industry,s first fully hardware encapsulated fingerprint sensor ... authentication technology is literally off the grid, ... biometric matching within the fingerprint sensor to ...
(Date:7/7/2015)... , June 30, 2015 ... has announced the addition of the "Capacitive ... offering. To this date, fingerprint sensing ... technology and fingerprint sensors are well developed. This ... sensing technology. The domain of capacitive ...
(Date:7/2/2015)... -- Fingerprint Cards has received an order for ... the distributor World Peace Industrial Group (WPI), part of WPG ... Asia . Deliveries are planned to take place during ... smartphone manufacturers in Asia . The order ... guidance of approximately 2,200 MSEK for 2015. Jörgen ...
Breaking Biology News(10 mins):Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2
... BOSTON Congenital heart diseases affect approximately one ... of birth defect and the number-one cause of pediatric deaths. ... inhibitor drug rapamycin can reverse cardiac muscle damage in a ... identifies the first possible medical treatment for this rare condition, ...
... Climate change is already having an effect on the ... taken it,s only going to get worse, a Michigan State ... the American Association for the Advancement of Science. Ewen ... organized a session titled "How Climate Change Affects the Safety ...
... attention has focused on issues such as the challenges ... pharmaceutical companies have invested comparatively little effort in updating ... inefficient, under-utilized and ill-equipped to cope with new medicines, ... latest report in the Pharma 2020 series, ...
Cached Biology News:Study shows rapamycin reverses myocardial defects in mouse model of LEOPARD syndrome 2Study shows rapamycin reverses myocardial defects in mouse model of LEOPARD syndrome 3Pharmaceutical Supply Chains Are Due for a Radical Overhaul Says PwC 2Pharmaceutical Supply Chains Are Due for a Radical Overhaul Says PwC 3Pharmaceutical Supply Chains Are Due for a Radical Overhaul Says PwC 4Pharmaceutical Supply Chains Are Due for a Radical Overhaul Says PwC 5
CASPR (H-66)...
Mouse monoclonal [PRMT5-21] to PRMT5 ( Abpromise for all tested applications). entrezGeneID: 10419 SwissProtID: O14744...
Mouse Nodal Affinity Purified Polyclonal Ab...
Normal sheep serum collected from healthy normal sheep...
Biology Products: